A Novel Direct Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease - <i>In Vivo</i> Efficacy of Ilx-002 in Humanized Mice
Osheiza Abdulmalik(Children's Hospital of Philadelphia), Andrew N. Fleischman, R. Clark Brown(Chrysalis BioTherapeutics (United States)), Akua K. Donkor(Virginia Commonwealth University), Moustafa E. El‐Araby(King Abdulaziz University), Abdelsattar M. Omar(Al-Azhar University), Veronica Bochenek(Children's Hospital of Philadelphia), Kandace Gollomp(Children's Hospital of Philadelphia), David R. Light(Thermo Fisher Scientific (Norway)), Benita Balogun(Children's Hospital of Philadelphia), Yan Zhang(Virginia Commonwealth University), Conroy O. Field(Children's Hospital of Philadelphia), S. Roland(Children's Hospital of Philadelphia), Martin K. Safo(Virginia Commonwealth University)
Cited by 0
Related Papers
In vivo hematopoietic stem cell modification by mRNA delivery
|Science|2023|321
5‐hydroxymethyl‐2‐furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells<sup>†,‡</sup>
|British Journal of Haematology|2005|244
Sphingosine-1-phosphate promotes erythrocyte glycolysis and oxygen release for adaptation to high-altitude hypoxia
|Nature Communications|2016|212